The future leadership of the Food and Drug Administration remains highly uncertain following the surprise resignation of Commissioner Lester Crawford in September.
WASHINGTON, D.C.-The future leadership of the Food and Drug Administration remains highly uncertain following the surprise resignation of Commissioner Lester Crawford in September.
The White House named Andrew von Eschenbach, director of the National Cancer Institute (NCI) at the National Institutes of Health (NIH), as acting FDA commissioner, but he got into trouble for trying to keep his NCI hat while taking the helm of FDA. Although he handed over day-to-day leadership of NCI to a deputy, that move failed to fully appease critics concerned about inherent conflicts of interest in advocating for speedy access to new cancer treatments while overseeing the safety and effectiveness of those therapies. HHS Secretary Michael Leavitt has indicated that von Eschenbach is not likely to get the top job at FDA on a permanent basis.
DAY-TO-DAY DEALINGS
But the uncertain atmosphere at FDA is making it difficult to move forward with important initiatives. A much-anticipated white paper on generic versions of costly biotech therapies, for example, has been delayed while the lawyers further examine policy and legal issues. FDA also plays a central role in ensuring public access to vaccines and therapies to guard against a possible flu epidemic, responsibilities that require strong leadership and ample resources.
All sides are looking to see if von Eschenbach bites the bullet and approves non-prescription use of Plan B, but as a close friend of President Bush, FDA's current leader may not be willing to do so.
Today, the clade 2b outbreak has reached alarming proportions, with over 94,000 confirmed cases reported across 117 countries, including significant numbers in the U.S. and Brazil, and up to 103 deaths. The virus has been found to affect younger men who have sex with men, who are linked to high rates of HIV co-infection.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen